Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.660
-0.030 (-1.78%)
At close: Apr 28, 2026, 4:00 PM EDT
1.699
+0.038 (2.32%)
After-hours: Apr 28, 2026, 7:55 PM EDT
Lexicon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Lexicon Pharmaceuticals stock have an average target of 4.15, with a low estimate of 2.30 and a high estimate of 6.00. The average target predicts an increase of 150.00% from the current stock price of 1.66.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 23, 2026.
Analyst Ratings
The average analyst rating for Lexicon Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +261.45% | Mar 23, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $2.1 → $2.3 | Strong Buy | Maintains | $2.1 → $2.3 | +38.55% | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $6 | Strong Buy | Maintains | $4 → $6 | +261.45% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +140.96% | Sep 2, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $1.2 → $1.9 | Strong Buy | Maintains | $1.2 → $1.9 | +14.46% | Aug 7, 2025 |
Financial Forecast
Revenue This Year
34.60M
from 49.80M
Decreased by -30.52%
Revenue Next Year
20.03M
from 34.60M
Decreased by -42.12%
EPS This Year
-0.18
from -0.14
EPS Next Year
-0.21
from -0.18
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 37.8M | 58.5M | ||||||
| Avg | 34.6M | 20.0M | ||||||
| Low | 29.4M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -24.1% | 69.0% | ||||||
| Avg | -30.5% | -42.1% | ||||||
| Low | -41.0% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.16 | -0.15 | ||||||
| Avg | -0.18 | -0.21 | ||||||
| Low | -0.20 | -0.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.